Amneal Pharmaceuticals Inc- 详细介绍、公司背景、业务范围、财务数据以及市场表现

关于 Amneal Pharmaceuticals Inc 公司

Amneal Pharmaceuticals, Inc. 是一家全球性制药公司，开发、生产、营销和分销一系列基本药物。其仿制药部门包括超过 270 个产品系列的零售和机构产品组合，涵盖一系列剂型和给药系统，包括速释和缓释口服固体、粉末、液体、无菌注射剂、鼻喷雾剂、吸入和呼吸产品、生物仿制药、眼科、薄膜、透皮贴剂和外用药。其专科部门从事品牌药品的开发、推广、销售和分销，重点是治疗中枢神经系统疾病（包括帕金森病和内分泌疾病）的产品。其 AvKARE 部门主要向政府机构提供药品、医疗和外科产品和服务，主要针对美国国防部和美国退伍军人事务部。

公司简介

公司代码AMRX

公司名称Amneal Pharmaceuticals Inc

上市日期Nov 18, 2009

CEOMr. Chintu Patel

员工数量8100

证券类型Ordinary Share

年结日Nov 18

公司地址400 Crossing Boulevard, 3rd Floor

城市BRIDGEWATER

上市交易所NASDAQ Global Select Consolidated

国家United States of America

邮编08807

电话19089473120

网址https://amneal.com/

公司代码AMRX

上市日期Nov 18, 2009

CEOMr. Chintu Patel

公司高管

名称

名称/职务

职务

持股

持股变动

Mr. Chintu Patel

Co-Chief Executive Officer, Co-Founder, Director

25.62M

+1.39%

Mr. Gautam Patel

Director

1.61M

-8.60%

Mr. Anastasios G. (Tasos) Konidaris

Chief Financial Officer, Executive Vice President

621.88K

+32.21%

Mr. Shlomo Yanai

Independent Director

285.99K

+16.38%

Ms. Nikita Shah

Chief Human Resources Officer, Executive Vice President

191.40K

-55.89%

Ms. Deborah M. (Deb) Autor

Independent Director

93.66K

+75.39%

Mr. Chirag Patel

President, Co-Chief Executive Officer, Co-Founder, Director

--

Mr. Ted Nark

Independent Director

--

Mr. Paul M. Meister

Independent Chairman of the Board

--

Mr. John J. Kiely

Independent Director

--

名称

名称/职务

职务

持股

持股变动

Mr. Chintu Patel

Co-Chief Executive Officer, Co-Founder, Director

25.62M

+1.39%

Mr. Gautam Patel

Director

1.61M

-8.60%

Mr. Anastasios G. (Tasos) Konidaris

Chief Financial Officer, Executive Vice President

621.88K

+32.21%

Mr. Shlomo Yanai

Independent Director

285.99K

+16.38%

Ms. Nikita Shah

Chief Human Resources Officer, Executive Vice President

191.40K

-55.89%

Ms. Deborah M. (Deb) Autor

Independent Director

93.66K

+75.39%

收入明细

单位: USD更新时间: 7月6日周日

FY2025Q1

FY2024

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

业务USD

名称

营收

占比

Oral solid

178.95M

25.73%

Distribution

104.89M

15.08%

Central Nervous System

67.61M

9.72%

Other dosage forms

56.42M

8.11%

Government label

50.14M

7.21%

其他

237.40M

34.14%

暂无数据

业务

地区

业务USD

名称

营收

占比

Oral solid

178.95M

25.73%

Distribution

104.89M

15.08%

Central Nervous System

67.61M

9.72%

Other dosage forms

56.42M

8.11%

Government label

50.14M

7.21%

其他

237.40M

34.14%

股东统计

更新时间: 8月15日周五

持股股东

股东类型

持股股东

占比

Patel (Tushar Bhikhubhai)

15.47%

Patel (Chintu)

8.16%

Patel (Dipan)

7.59%

Patel (Chirag K)

7.05%

Akram (Mahesh)

6.55%

其他

55.20%

持股股东

占比

Patel (Tushar Bhikhubhai)

15.47%

Patel (Chintu)

8.16%

Patel (Dipan)

7.59%

Patel (Chirag K)

7.05%

Akram (Mahesh)

6.55%

其他

55.20%

股东类型

持股股东

占比

Individual Investor

46.44%

Investment Advisor

17.42%

Hedge Fund

12.07%

Investment Advisor/Hedge Fund

10.83%

Private Equity

3.93%

Research Firm

1.21%

Pension Fund

0.24%

Bank and Trust

0.20%

Family Office

0.02%

其他

7.65%

机构持股

更新时间: 7月1日周二

报告期

机构数

持股数

持股占比

持股变动

2025Q2

430

283.67M

90.50%

-32.81M

2025Q1

437

285.44M

91.08%

-30.39M

2024Q4

413

285.94M

92.29%

-32.70M

2024Q3

398

304.85M

98.50%

-8.45M

2024Q2

391

304.30M

98.56%

+52.65M

2024Q1

375

272.60M

88.40%

+17.73M

2023Q4

366

275.21M

90.82%

+129.07M

2023Q3

354

120.75M

78.38%

-3.68M

2023Q2

353

115.91M

75.59%

-7.89M

2023Q1

359

114.33M

74.58%

-11.39M

股东持股明细

名称

持股数

占比

持股变动

变动比例

公告日期

Patel (Tushar Bhikhubhai)

48.58M

15.5%

-5.00M

-9.33%

Mar 14, 2025

Patel (Chintu)

25.62M

8.17%

+351.47K

+1.39%

Mar 14, 2025

Patel (Dipan)

23.83M

7.6%

--

Mar 14, 2025

Patel (Chirag K)

22.13M

7.06%

+345.41K

+1.59%

Mar 14, 2025

Akram (Mahesh)

20.56M

6.56%

-6.30M

-23.45%

Mar 31, 2025

The Vanguard Group, Inc.

15.71M

5.01%

+920.76K

+6.23%

Mar 31, 2025

TPG Capital, L.P.

12.33M

3.93%

--

Mar 31, 2025

Rubric Capital Management LP

10.74M

3.43%

+14.20K

+0.13%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

11.14M

3.55%

-80.92K

-0.72%

Mar 31, 2025

Citadel Advisors LLC

7.49M

2.39%

-1.49M

-16.58%

Mar 31, 2025

持股ETF

更新时间: 9月6日周六

机构名称

占比

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

2.3%

Vanguard US Multifactor ETF

0.22%

First Trust Multicap Growth Alphadex Fund

0.12%

JPMorgan BetaBuilders US Small Cap Equity ETF

0.06%

Global X Russell 2000 ETF

0.05%

iShares Morningstar Small-Cap Value ETF

0.04%

Fidelity MSCI Health Care Index ETF

0.03%

Dimensional US Core Equity 1 ETF

0.01%

DFA Dimensional US Core Equity Market ETF

0%

iShares Russell 3000 ETF

0%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

占比2.3%

Vanguard US Multifactor ETF

占比0.22%

First Trust Multicap Growth Alphadex Fund

占比0.12%

JPMorgan BetaBuilders US Small Cap Equity ETF

占比0.06%

Global X Russell 2000 ETF

占比0.05%

iShares Morningstar Small-Cap Value ETF

占比0.04%

Fidelity MSCI Health Care Index ETF

占比0.03%

Dimensional US Core Equity 1 ETF

占比0.01%

DFA Dimensional US Core Equity Market ETF

占比0%

iShares Russell 3000 ETF

占比0%

分红派息

近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股

公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

Amneal Pharmaceuticals Inc

9.810USD

Amneal Pharmaceuticals Inc

9.810

概览

公司

财务

分析